Skip to Content
Merck
  • Foscarnet salvage therapy for acyclovir-resistant varicella zoster: report of a novel thymidine kinase mutation and review of the literature.

Foscarnet salvage therapy for acyclovir-resistant varicella zoster: report of a novel thymidine kinase mutation and review of the literature.

The Pediatric infectious disease journal (2007-12-29)
Todd Hatchette, Graham A Tipples, Geoff Peters, Ahmed Alsuwaidi, Jianwei Zhou, Timothy Lloyd Mailman
ABSTRACT

The authors describe an acyclovir-resistant varicella zoster virus infection in a pediatric patient after hematopoietic stem cell transplant, the use of foscarnet as salvage therapy, and review the literature to clarify the pediatric experience with foscarnet in this setting. A novel thymidine kinase mutation is described, along with a new phenotypic assay for characterizing acyclovir resistance in varicella zoster virus.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Acycloguanosine, ≥99% (HPLC), powder
Aciclovir, European Pharmacopoeia (EP) Reference Standard
USP
Acyclovir, United States Pharmacopeia (USP) Reference Standard
Supelco
Acyclovir, Pharmaceutical Secondary Standard; Certified Reference Material
Aciclovir for system suitability, European Pharmacopoeia (EP) Reference Standard
Aciclovir for peak identification 1, European Pharmacopoeia (EP) Reference Standard